Form 8-K - Current report:
SEC Accession No. 0001104659-25-070376
Filing Date
2025-07-24
Accepted
2025-07-24 16:15:35
Documents
16
Period of Report
2025-07-21
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2521365d1_8k.htm   iXBRL 8-K 27245
2 EXHIBIT 16.1 tm2521365d1_ex16-1.htm EX-16.1 2801
6 GRAPHIC tn2521365d1_ex16-1img001.jpg GRAPHIC 4518
7 GRAPHIC tn2521365d1_ex16-1img002.jpg GRAPHIC 6231
8 GRAPHIC tn2521365d1_ex16-1img003.jpg GRAPHIC 38249
  Complete submission text file 0001104659-25-070376.txt   264751

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bzyr-20250721.xsd EX-101.SCH 3041
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bzyr-20250721_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bzyr-20250721_pre.xml EX-101.PRE 22376
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2521365d1_8k_htm.xml XML 3657
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0228
Type: 8-K | Act: 34 | File No.: 000-23425 | Film No.: 251147060
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)